A longitudinal trial launched to evaluate change over time in oculometric Biomarkers in Parkinson’s Disease

NeuraLight has launched a longitudinal trial titled “Evaluation of Oculometric Measures and Clinical Assessment Over Time in Parkinson’s Disease” — designed to explore how oculometric measures change over time, compared with established clinical assessments in Parkinson’s disease (PD).

Registered as NCT05795023 on ClinicalTrials.gov, the study is being conducted at the Sourasky Tel Aviv Medical Center under the leadership of Prof. Roy Alcalay, and with Prof. Tanya Gurevich as a prinicipal investigator, both leading movement disorders specialists with vast experience in global clinical trials.

Over a nine-month period, patients with idiopathic Parkinson’s disease complete routine motor and cognitive clinical evaluations, alongside oculometric assessments conducted using the NeuraLight platform.

By examining how oculometric measures change over time, the study aims to further validate eye movements as an objective and sensitive biomarker of Parkinson’s disease progression.

The study represents another important step in NeuraLight’s mission to transform neurology and care through precise, AI-driven biomarkers.